ArticlePloS one2025
Bioactive fungal metabolites as SIRT2 antagonists: A computational quest for cancer treatment.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SIRT2, a member of the sirtuin protein family, plays a pivotal role in regulating tumor progression by modulating key metabolic pathways and signaling proteins. The regulatory role of this protein has been documented across a variety of cancers. Emphasizing its role in cancer biology, this study employed computer aided drug design (CADD) approach, including molecular docking, dynamics and pharmacoinformatics, to screen fungal metabolites as potential anticancer agents. Subsequent assessments of pharmacokinetics and toxicity revealed that all tested fungal metabolites possessed oral bioavailability, drug-like characteristics, and favorable ADMET profiles. The metabolites also exhibited no hepatotoxicity, carcinogenicity, or mutagenicity, highlighting their significant therapeutic potential and favorable safety profile. The docking analysis further revealed strong binding affinities of the metabolites with the SIRT2, with the MSID001658 showing the highest score (-10.9 kcal/mol), followed by the MSID000672 (-10.2 kcal/mol). Further molecular dynamics simulation evaluated the structural and dynamic stabilities of the SIRT2 in association with the ligands. Although both complexes showed overall stability, the MSID000672 had larger RMSD variations, whereas the MSID001658 maintained consistent structural integrity throughout the simulation. Furthermore, the binding of MSID000672 was associated with increased solvent exposure, in contrast to the more compact molecular surface area (MolSA) and radius of gyration (Rg) profile observed for the MSID001658. The PCA indicated compact clustering (53.6%) for the SIRT2_MSID000672 complex, whereas the SIRT2_MSID001658 had a larger variance (70.9%) of flexibility. The DCCM further revealed enhanced coordination of internal movements in the SIRT2_MSID000672 complexes. Finally, the MSID001658 fosters a compact, stable complex with the SIRT2, whereas the MSID000672 increases conformational flexibility and solvent accessibility. These results support the notion that the MSID000672 might be an effective anticancer agent if subjected to more experimental trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.